PROFILPELAJAR.COM

Tixagevimab

Tixagevimab er et monoklonalt antistoff (MAK) som (mars 2021) er under utprøving i den medisinske behandling av covid-19-pasienter. Det benyttes i kombinasjon med MAK Cilgavimab (som antistoffkombinasjon under navnet AZD7442[1]). Det utvikles av AstraZeneca.

Tixagevimab ble fremstilt rekombinant i ovarialceller fra grå dverghamster (CHO-celler). Antistoffets tunge gamma-kjede består av 461 aminosyrer, den lette kappa-kjeden av 219 aminosyrer.[2] Medikamentet sikter seg inn mot SARS-CoV-2-virusets piggprotein. Strukturen i et isolert antistoff av type IgG1 fra serumet av covid-19-rekonvalescent ble således modifisert at molekylet forblir lengre i kroppen enn et fysiologisk antistoff (Long Acting Antibody, LAAB). Slik skal det også kunne beskytte mot SARS-CoV-2-infeksjon i seks til tolv måneder.[1]

Referanser

  1. ^ a b SARS-CoV-2-Antikörper in Phase III, www.pharmazeutische-zeitung.de, lest 2021-03-12
  2. ^ Proposed INN: List 124 – COVID-19 (special edition).  Ekstern lenke i |title= (hjelp)

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.